This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hamadani M, Craig M, Awan FT, Devine SM . How we approach patient evaluation for hematopoietic stem cell transplantation. Bone Marrow Transplant 2010; 45: 1259–1268.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.
Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104: 961–968.
Extermann M . Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000; 35: 181–200.
Sengsayadeth S, Savani BN, Blaise D, Malard F, Nagler A, Mohty M . Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission-a review from the Acute Leukemia Working Party of the EBMT. Haematologica 2015; 100: 859–869.
Russell NH, Kjeldsen L, Craddock C, Pagliuca A, Yin JA, Clark RE et al. A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia. Leukemia 2015; 29: 1478–1484.
Platzbecker U . Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights. Hematology Am Soc Hematol Educ Program 2013; 2013: 522–528.
Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 2015; 125: 1333–1338.
Bolanos-Meade JKJ, Reshef R . A Multicenter Phase II Trial Randomizing Novel Approaches for Graft-versus-host Disease Prevention Compared to Contemporary Controls (1203). Available at https://clinicaltrials.gov/ct2/show/NCT02208037. Accessed on 19 January 2015.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on Bone Marrow Transplantation website
Supplementary information
Rights and permissions
About this article
Cite this article
Nazha, A., Rybicki, L., Abounader, D. et al. GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies. Bone Marrow Transplant 51, 1642–1643 (2016). https://doi.org/10.1038/bmt.2016.254
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.254